According to Panigrahy (32), EPHX2 inhibitors can promote the progression of melanoma and fibrosarcoma in mouse models by increasing the level of an endogenous lipid mediator, epoxy eicosatrienoic acid (EETs) (32), suggesting that a relationship exists between EPHX2-lipid metabolism and tumor progression. Here, EPHX2 is linked to fibrosarcoma.